The Anti-PD-1 MAb Market is expanding as immune checkpoint inhibitors gain increasing importance in the treatment of cancer. Anti-PD-1 monoclonal antibodies (MAbs) are designed to block the programmed cell death protein 1 (PD-1) pathway, helping restore T-cell activity against cancer cells. These therapies are used across several oncology applications, either as monotherapies or in combination...